Dickkopf-1 and β-catenin as Biomarkers for Early Diagnosis of Hepatocellular Carcinoma (original) (raw)
Related papers
Oncology Reports, 2011
the global rising incidence of hepatocellular carcinoma (HCC), which parallels the increase of hepatitis C virus (HCV) prevalence, has sparked a renewed interest in discovering additional HCC serum markers. In this study, we investigated the clinical use of serum e-cadherin, ICAM, MMp-2, VeGF, OpN and β-catenin as potential diagnostic makers for HCV/genotype 4-associated HCC. twenty cases of healthy subjects, 11 cases with asymptomatic HCV/genotype 4 carriers (AsC), 28 cases of chronic hepatitis (CH) cases and 32 patients with HCC were enrolled in this study. serum levels of proteins were measured by a sandwich-enzymelinked (eLIsA) assay. the diagnostic accuracy of each candidate marker was evaluated using receiver-operating characteristic (rOC) curve analysis, reporting the area under the curve (AUC) and its 95% confidence interval (CI). We demonstrated that serum β-catenin levels were significantly elevated in patients with HCC compared to those with CH, AsC and healthy controls. Among the six studied markers, β-catenin was also found to be the only marker that can significantly discriminate between patients with HCC and those with CH; therefore, β-catenin could be considered as a potential marker for early diagnosis of HCV-associated HCC in patients infected with HCV genotype 4.
Alpha Fetoprotein; Useful as Screening Test for Hepatocellular Carcinoma Due to Chronic Hepatitis C
THE PROFESSIONAL MEDICAL JOURNAL
ORIGINAL PROF-3690 ABSTRACT… BACKGROUND: Hepatocellular carcinoma (HCC) is a primary tumor of the liver, which develops in the setting of chronic liver disease, particularly in patients with chronic hepatitis B and C in almost 80% patients. Although there are no specific screening tests for diagnosis of HCC but alpha-fetoprotein (AFP) and abdominal ultrasound are commonly used. AFP >400 ng/ml is considered diagnostic for HCC. Objective: The objective of study was to validate the use of alphafetoprotein as screening test for HCC due to chronic HCV. Study Design: Observational cross-sectional. Period: March 2014 to August 2016. Setting: Aziz Bhatti Shaheed Teaching Hospital Gujrat. Materials and Methods: 134 patients aged >35 years having liver cirrhosis due to chronic HCV and diagnosed with HCC using biphasic CT scan were included and were followed for 1 year. Serum AFP was divided in 3 categories and a value < 20ng/ml-normal, 20-399 ng/ml-elevated and >400ng/ml-diagnostic of HCC. Liver nodules size and site was noted and divided in 4 categories. Severity of liver disease was calculated using Child Pugh Score. Analysis was done using SPSS 20.0. Results: AFP is diagnostic (>400 ng/ml) in only 29.9% of patients with sensitivity of 43.3% at cut off value of 400 ng/ml and is significantly associated with severity of liver disease. Conclusion: AFP cannot be used as screening test for HCC in patients with cirrhosis due to chronic HCV. Abdominal ultrasound should be used for early detection of HCC due to chronic hepatitis C.
Evaluation of HCV-associated Hepatocellular Carcinoma based on Alpha-fetoprotein levels
Afro-Egyptian Journal of Infectious and Endemic Diseases, 2019
Background and study aim: Alphafetoprotein (AFP) cannot be relied on alone for diagnosis of hepatocellular carcinoma (HCC). However, it may have a prognostic value and can be used for monitoring response to different modalities of treatment for HCC. This study aimed to differentiate the clinical and pathological features of HCCs according to AFP levels. Subjects and Methods: This retrospective study included 60 patients with HCC secondary to chronic hepatitis C (HCV). They were divided based on serum AFP into two groups; group I; included 30 patients with AFP lower than 302.5ng/ml. and group II; included 30 patients with AFP higher than 302.5ng/ml. clinical, laboratory and pathological differences between both groups were compared. Results: Regarding the pathological features, patients with higher AFP secreting tumors have larger tumor size compared to lower AFP secreting tumors; (5.8 cm Vs. 4.5 cm, P value; 0.001). Number of lesions and tumor location were similar between the two groups. Conclusion: HCC-secreting high levels of AFP are larger and aggressive tumors when compared to low secreting AFP-HCC.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017
Background: The utility of alpha-fetoprotein (AFP) for hepatocellular carcinoma (HCC) surveillance is controversial. We aimed to identify factors associated with elevated AFP and define the patients for whom AFP is effective for surveillance.Methods: Data from the NCI Early Detection Research Network phase II HCC biomarker study (233 early-stage HCC and 412 cirrhotic patients) were analyzed. We analyzed 110 early-stage HCC and 362 cirrhotic hepatitis C virus (HCV) patients for external validation. Sensitivity, specificity, and area under the ROC curve (AUC) for HCC were calculated.Results: HCV etiology, non-White race, and serum alanine transaminase (ALT) predicted elevated AFP in cirrhotics. Non-White race and ALT predicted elevated AFP in HCC patients. Higher AUC of AFP for HCC was noted in patients with HBV (0.85) and alcohol (0.84), whereas it was lower in patients with hepatitis C virus (HCV; 0.80) and nonviral/alcohol etiology (0.76). The AUC was higher in HCV patients with se...
Abstract Objective: Hepatocellular carcinoma (HCC) is the most frequent and severe complication of chronic liver diseases. It represents an important public health problem in Egypt, where up to 90% of HCC cases are attributable to hepatitis C virus (HCV) infection. The objective of the present study was to assess a panel of biomarkers that can significantly differentiate between HCC and non-HCC patients with chronic HCV infection (CHC), quantitatively. Methods: A total of 75 adult male patients with CHC were divided into 3 main groups according to liver involvement: HCV without cirrhosis (CHC), patients with cirrhotic liver (LC), and HCC patients. Liver function, lipid profile, HBsAg, HCV antibodies, alpha-fetoprotein (AFP), insulin-like growth factor II (IGF-II), heparanase (HPSE), and lipid peroxidation were assayed. Results: The AST/ALT ratio, AFP, and HPSE were significantly different in the HCC group with the optimum cut-off values as ≥ 1.92, 64.7 ng/ml and 5.6 U/ml, respectively. By using these cut-off values combined; 96% of HCC patients showed two abnormal markers, corresponding to only 29% of the LC group. Conclusion: The use of combined HPSE, AFP and AST/ALT ratio cut-off values improved the positive predictive value for HCC from 79% to 96%. Key words: Alpha-fetoprotein; AST/ALT ratio; Heparanase; Hepatocellular carcinoma; IGF-II
Disease Markers, 2011
Serum alpha fetoprotein (AFP) is the most widely used tumor marker in detecting patients with hepatocellular carcinoma (HCC). However, it has been indicated that HCCR-1 (human cervical cancer oncogene 1) might be supplementary to AFP in the detection. We conducted a prospective study in 120 normal and 524 liver disease patients to evaluate the significance of simultaneous measurement of 2 tumor markers (AFP and HCCR-1) in the diagnosis of HCC through the cohort study in Korea and China. We also performed immunohistochemical studies using 25 normal subjects (N), 32 liver cirrhosis (LC) and 116 HCC tissues. The sensitivities of AFP (20 ng/mL) and HCCR-1 (10 ng/mL) in HCC were 55.8% (164/294) and 44.2% (130/294), respectively. When AFP was combined with HCCR-1, sensitivities increased to 4.2% (N), 12.7% (chronic hepatitis; CH), 50.0% (LC), and 77.2% (HCC), respectively. Although there was no significant difference in the diagnostic rate for HCC between AFP and HCCR-1, many cases for AF...
Open Access Macedonian Journal of Medical Sciences, 2018
BACKGROUND: AFP serum levels are considered as diagnostic and specific for hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC). AIM: This study aimed to examine the diagnostic value of AFP in the distinguishing of patients with HCC from patients with LC, and to analyse the potential correlation between AFP levels and liver disease stages. MATERIAL AND METHODS: Fifty patients with LC and fifty patients with HCC were included in this study. The majority of the patients were males, while the HBV aetiology was dominant. RESULTS: Significant differences between LC and HCC patients were detected for AST, ALT, GGT, bilirubin, AFP and AP. Patients with HCC had higher AFP values compared to LC. There was no significant correlation between the size of the tumour lesion and serum AFP levels. A positive correlation between AFP concentration and GGT activity was determined, as was the negative correlation between AFP and age of the subjects. The AFP value of 23.34 ng/m showed hi...
BMC Cancer, 2007
Background: Hepatocellular carcinoma is the most common cause of primary liver neoplasms and is one of the main causes of death in patients with liver cirrhosis. High Alpha fetoprotein serum levels have been found in 60-70% of patients with Hepatocellular carcinoma; nevertheless, there are other causes that increase this protein. Alpha fetoprotein levels ≥200 and 400 ng/mL in patients with an identifiable liver mass by imaging techniques are diagnostic of hepatocellular carcinoma with high specificity.